Macrovascular complications of diabetes in older adults

Geriatric Diabetes

Volumn , Issue , 2007, Pages 169-182

  Scranton, Richard E ^a   Dave, Jatin K ^a   Michael Gaziano, J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70449911555     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (72)

1. Engelgau MM, Geiss LS, Saaddine JB, et al. The evolving diabetes burden in the United States. Ann Intern Med 2004; 140(11): 945-950.
2. Geiss LS, Pan L, Cadwell B, Gregg EW, Benjamin SM, Engelgau MM. Changes in incidence of diabetes in U.S. Adults, 1997-2003. Am J Prev Med 2006; 30(5): 371-377.
3. Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabet Care 2001; 24(11): 1936-1940.
4. Stolk RP, Pols HA, Lamberts SW, de Jong PT, Hofman A, Grobbee DE. Diabetes mellitus, impaired glucose tolerance, and hyperinsulinemia in an elderly population. The Rotterdam Study. Am J Epidemiol 1997; 145(1): 24-32.
5. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000; 101(9): 975-980.
6. Lawler EGJ, Scranton RE. Use of HOMA-IR to assess the risk of incident diabetes among men with normal fasting blood sugar in abstract. Diabetologia 2005; 48(suppl 1): A58.
7. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287(19): 2570-2581.
8. Geiss LS, Herman WH, Smith PJ. Mortality in non-insulin-dependent diabetes. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH, eds. Diabetes in America. Washington, DC: U.S. Govt. Printing Office, 1995: 233-257.
9. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999; 281(14): 1291-1297.
10. Smith JW, Marcus FI, Serokman R. Prognosis of patients with diabetes mellitus after acute myocardial infarction. Am J Cardiol 1984; 54(7): 718-721.
11. Wannamethee SG, Shaper AG, Lennon L. Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease. Heart 2004; 90(12): 1398-403.
12. Himmelmann A, Hansson L, Svensson A, Harmsen P, Holmgren C, Svanborg A. Predictors of stroke in the elderly. Acta Med Scand 1988; 224(5): 439-443.
13. Strachan M. Cognitive decline and the older patient with diabetes. Clin Geriat 2002; 10(6).
14. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001; 154(7): 635-641.
15. Hankey GJ, Jamrozik K, Broadhurst RJ, et al. Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke 1998; 29(12): 2491-2500.
16. Akbari CM, LoGerfo FW. Diabetes and peripheral vascular disease. J Vasc Surg 1999; 30(2): 373-384.
17. NCHS. Health, United States, 2005, with Chartbook on Trends in the Health of Americans with special feature on adults 55-64 years, 2005. NCHS.
18. Lawler. Morbidity, Mortality, and Exceptional Longevity. Boston: Boston University; 2006.
19. Ness J, Nassimiha D, Feria MI, Aronow WS. Diabetes mellitus in older African-Americans, Hispanics, and Whites in an academic hospital-based geriatrics practice. Coron Artery Dis 1999; 10(5): 343-346.
20. Insua JT, Sacks HS, Lau TS, et al. Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med 1994; 121(5): 355-362.
21. Langer RD, Criqui MH, Barrett-Connor EL, Klauber MR, Ganiats TG. Blood pressure change and survival after age 75. Hypertension 1993; 22(4): 551-559.
22. Langer RD, Ganiats TG, Barrett-Connor E. Paradoxical survival of elderly men with high blood pressure. BMJ 1989; 298(6684): 1356-1357.
23. Langer RD, Ganiats TG, Barrett-Connor E. Factors associated with paradoxical survival at higher blood pressures in the very old. Am J Epidemiol 1991; 134(1): 29-38.
24. Manolio TA, Pearson TA, Wenger NK, Barrett-Connor E, Payne GH, Harlan WR. Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol 1992; 2(1-2): 161-176.
25. Laakso M. Glycemic control and the risk for coronary heart disease in patients with non-insulindependent diabetes mellitus. The Finnish studies. Ann Intern Med 1996; 124(1 Pt 2): 127-130.
26. Frost PH, Davis BR, Burlando AJ, et al. Coronary heart disease risk factors in men and women aged 60 years and older: findings from the Systolic Hypertension in the Elderly Program. Circulation 1996; 94(1): 26-34.
27. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991; 1(3): 263-276.
28. Smith NL, Barzilay JI, Shaffer D, et al. Fasting and 2-hour postchallenge serum glucose measures and risk of incident cardiovascular events in the elderly: the Cardiovascular Health Study. Arch Intern Med 2002; 162(2): 209-216.
29. Balkau B. The DECODE study. Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe. Diabetes Metab 2000; 26(4): 282-286.
30. Kuizon D, Gordon SM, Dolmatch BL. Single-lumen subcutaneous ports inserted by interventional radiologists in patients undergoing chemotherapy: incidence of infection and outcome of attempted catheter salvage. Arch Intern Med 2001; 161(3): 406-410.
31. Park S, Barrett-Connor E, Wingard DL, Shan J, Edelstein S. GHb is a better predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women without diabetes. The Rancho Bernardo Study. Diabetes Care 1996; 19(5): 450-456.
32. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 1998; 21(8): 1236-1239.
33. Standards of medical care in diabetes-2006. Diabetes Care 2006; 29(suppl 1): S4-S42.
34. Olson DE, Norris SL. Diabetes in older adults. Overview of AGS guidelines for the treatment of diabetes mellitus in geriatric populations. Geriatrics 2004; 59(4): 18-24; quiz 5.
35. Young JC. Diagnosis of CAD in patients with diabetes: who to Evaluate. Curr Diab Rep 2003; 3(1): 19-27.
36. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective Pioglitzone Clinical Trial in Macrovascular Events): a randomised controlled trial. Lancet 2005; 366(9493): 1279-1289.
37. Skyler J. PROactive: a sad tale of inappropriate analysis and unjustified interpretation. Clin Diabet 2006; 24(2): 63-65.
38. Freemantle N. How well does the evidence on pioglitazone back up researchers’ claims for a reduction in macrovascular events? BMJ 2005; 331(7520): 836-868.
39. Yki-Jarvinen H. The PROactive study: some answers, many questions. Lancet 2005; 366(9493): 1241-1242.
40. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110(2): 227-239.
41. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289(19): 2560-2572.
42. Wei M, Gibbons LW, Mitchell TL, Kampert JB, Lee CD, Blair SN. The association between cardiorespiratory fitness and impaired fasting glucose and type 2 diabetes mellitus in men. Ann Intern Med 1999; 130(2): 89-96.
43. Haire-Joshu D, Glasgow RE, Tibbs TL. Smoking and diabetes. Diabetes Care 2004; 27(suppl 1): S74-S75.
44. Harris MI, Eastman RC. Is there a glycemic threshold for mortality risk? Diabet Care 1998; 21(3): 331-333.
45. Kris-Etherton PM. AHA science advisory: monounsaturated fatty acids and risk of cardiovascular disease. J Nutr 1999; 129(12): 2280-2284.
46. Hu FB, Stampfer MJ, Rimm EB, et al. A prospective study of egg consumption and risk of cardiovascular disease in men and women. JAMA 1999; 281(15): 1387-1394.
47. Goldberg RJ, Larson M, Levy D. Factors associated with survival to 75 years of age in middle-aged men and women. The Framingham Study. Arch Intern Med 1996; 156(5): 505-509.
48. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265(24): 3255-3264.
49. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350(9080): 757-764.
50. Wang JG, Staessen JA, Gong L, Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med 2000; 160(2): 211-220.
51. Staessen JA, Wang JG, Thijs L, Fagard R. Overview of the outcome trials in older patients with isolated systolic hypertension. J Jum Hyper 1999; 10: 735-742.
52. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355(9207): 865-872.
53. Marks J. Treating hypertension in diabetes: data and perspectives. Clin Diabet 1999; 17.
54. Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 2003; 138: 593-602.
55. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351(9118): 1755-1762.
56. Mungall MM, Gaw A, Shepherd J. Statin therapy in the elderly: does it make good clinical and economic sense? Drugs Aging 2003; 20(4): 263-275.
57. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288(23): 2998-3007.
58. Simons LA, Simons J, Friedlander Y, McCallum J. Cholesterol and other lipids predict coronary heart disease and ischaemic stroke in the elderly, but only in those below 70 years. Atherosclerosis 2001; 159(1): 201-208.
59. Shepherd J, Blauw GJ, Murphy MB, et al. The design of a PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. Am J Cardiol 1999; 84(10): 1192-1197.
60. Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med 2001; 134(10): 931-940.
61. Eaton CB, Lapane KL, Murphy JB, Hume AL. Effect of statin (HMG-Co-A-reductase inhibitor) use on 1-year mortality and hospitalization rates in older patients with cardiovascular disease living in nursing homes. J Am Geriatr Soc 2002; 50(8): 1389-1395.
62. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004; 291(15): 1864-1870.
63. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361(9364): 1149-1158.
64. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998; 129(9): 681-689.
65. Sever PS, Poulter NR, Dahlof B, et al. Reduction in cardiovascular events with atorvastatin in 2532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Diabet Care 2005; 28(5): 1151-1157.
66. Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 2004; 140(8): 650-658.
67. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364(9435): 685-696.
68. Colhoun HM, Betteridge DJ, Durrington PN, et al. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2005; 48(12): 2482-2485.
69. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366(9500): 1849-1861.
70. Johnston C. Impact of atorvastatin on cardiovascular events on older patients similiar to benefit in younger patients: presented at ISC. ISC, 2006.
71. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348(5): 383-393.
72. Newman AB, Arnold AM, Naydeck BL, et al. “Successful aging”: effect of subclinical cardiovascular disease. Arch Intern Med 2003; 163(19): 2315-2322.